MADRIGAL PHARMACEUTICALS, INC.
MDGLNasdaq
$553.48
↑ +1.5%Jul 17 close · end-of-day
Price
1Y↑ +60.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$16.1B
Enterprise Value
$15.6B
P/E
—
P/S
14.2
P/B
29.6
EV/EBITDA
—
PEG
—
FCF Yield
-1.7%
Dividend Yield
—
Revenue (TTM)
$1.1B
Net Income (TTM)
-$309.4M
Free Cash Flow (TTM)
-$272.4M
Gross Margin
—
Operating Margin
-27.7%
Net Margin
-27.3%
ROE
-56.9%
ROIC
-348.8%
Debt / Equity
0.6
Net Cash
$472.4M
Return 1Y
+58.7%
Company profile
Madrigal Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the. treatment of non-alcoholic steatohepatitis.
- CEO
- Paul A. Friedman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Pennsylvania
- Website
- madrigalpharma.com
Management & directors
- Soergel DavidChief Medical Officer
- Dier MardiEVP and CFO
- Huntsman CaroleChief Commercial Officer
- Kelley Shannon TGeneral Counsel
- Sibold William JohnPresident and CEO
- Thakkar RitaChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
MDGL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$311.3M↑ +126.8%
Diluted EPS-$3.25↑ +24.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $180.1M | $958.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$206.7M | -$242.5M | -$293.6M | -$380.5M | -$497.9M | -$300.1M |
| Net income | -$202.2M | -$241.8M | -$295.3M | -$373.6M | -$465.9M | -$288.3M |
| Diluted EPS | -$13.09 | -$14.63 | -$17.23 | -$17.33 | -$17.31 | -$10.15 |
| Operating cash flow | -$157.6M | -$183.9M | -$224.9M | -$324.2M | -$455.6M | -$189.6M |
| Free cash flow | -$157.9M | -$184.1M | -$225.1M | -$325.7M | -$457.0M | -$190.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -276.4% | -31.3% |
| Net margin | — | — | — | — | -258.6% | -30.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $62.2M | $103.3M | $137.3M | $212.8M | $287.3M | $321.1M | $311.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$162.5M | -$116.3M | -$67.0M | -$79.3M | -$47.2M | -$114.0M | -$59.6M | -$92.7M |
| Net income | -$152.0M | -$107.0M | -$59.4M | -$73.2M | -$42.3M | -$114.2M | -$58.6M | -$94.4M |
| Diluted EPS | -$7.10 | -$4.92 | $2.09 | -$2.61 | -$1.50 | -$4.01 | -$2.03 | -$3.25 |
| Operating cash flow | -$134.9M | -$67.0M | -$104.5M | -$88.9M | -$47.1M | $79.8M | -$133.5M | -$167.4M |
| Free cash flow | -$135.1M | -$67.8M | -$104.7M | -$88.9M | -$47.1M | $79.0M | -$133.8M | -$171.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1110.4% | -187.1% | -64.8% | -57.8% | -22.2% | -39.7% | -18.6% | -29.8% |
| Net margin | -1038.2% | -172.0% | -57.5% | -53.4% | -19.9% | -39.8% | -18.2% | -30.3% |
Company news
Jul 13, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-17 | Taub Rebecca | Award | 454 | $0.00 | $0.00 | filing |
| 2026-06-17 | Levy Richard S | Award | 454 | $0.00 | $0.00 | filing |
| 2026-06-17 | FOUSE JACQUALYN A | Award | 454 | $0.00 | $0.00 | filing |
| 2026-06-17 | Daly James M | Award | 454 | $0.00 | $0.00 | filing |
| 2026-06-17 | Brennan Daniel J. | Award | 404 | $0.00 | $0.00 | filing |
| 2026-06-17 | BAKER BROS. ADVISORS LP | Award | 908 | $0.00 | $0.00 | filing |
| 2026-06-17 | BAKER BROS. ADVISORS LP | Award | 908 | $0.00 | $0.00 | filing |
| 2026-06-01 | Soergel David· Chief Medical Officer | Sale | 1,042 | $495.74 | $516,561.08 | filing |
| 2026-05-22 | Levy Richard S | Sale | 1,497 | $517.59 | $774,835.37 | filing |
| 2026-05-22 | Levy Richard S | Sale | 782 | $518.76 | $405,668.76 | filing |
| 2026-05-22 | Levy Richard S | Sale | 723 | $516.87 | $373,693.97 | filing |
| 2026-05-22 | Levy Richard S | Sale | 657 | $515.92 | $338,960.69 | filing |
| 2026-05-22 | Levy Richard S | Sale | 610 | $511.40 | $311,951.99 | filing |
| 2026-05-22 | Levy Richard S | Sale | 439 | $512.50 | $224,988.47 | filing |
| 2026-05-22 | Levy Richard S | Sale | 343 | $514.67 | $176,531.50 | filing |
| 2026-05-22 | Levy Richard S | Sale | 320 | $508.24 | $162,637.44 | filing |
| 2026-05-22 | Levy Richard S | Sale | 151 | $510.36 | $77,064.04 | filing |
| 2026-05-22 | Levy Richard S | Sale | 80 | $519.98 | $41,598.40 | filing |
| 2026-05-22 | Levy Richard S | Sale | 40 | $512.97 | $20,518.80 | filing |
| 2026-05-22 | Levy Richard S | Sale | 40 | $506.68 | $20,267.00 | filing |
| 2026-05-18 | Soergel David· Chief Medical Officer | Sale | 844 | $515.90 | $435,419.60 | filing |
| 2026-03-06 | Sibold William John· President and CEO | Sale | 1,663 | $431.94 | $718,316.22 | filing |
| 2026-03-06 | Dier Mardi· EVP and CFO | Sale | 646 | $431.94 | $279,033.24 | filing |
| 2026-03-06 | Taub Rebecca | Sale | 491 | $431.94 | $212,082.54 | filing |
| 2026-03-06 | Huntsman Carole· Chief Commercial Officer | Sale | 419 | $431.94 | $180,982.86 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.